Home

Michael Richman

CIK 1366265 · President & CEO · last filed 2026-02-03

Michael Richman is a President & CEO who has filed 57 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for NXTC, was dated Feb 3, 2026. 25 SEC filings were submitted jointly with PALVELLA THERAPEUTICS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

6

Total Filings

57

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
2635 TECHNOLOGY FOREST BLVD.
HOUSTON, TX 77381
Related Filers
PALVELLA THERAPEUTICS, INC. — 25 joint filings, latest 2023-06-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NXTC President & CEO — $7.00 — $0 8 2026-02-03
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director — $13.60 — $0 24 2023-06-23
GENVEC INC (GNVC) Delisted Director — — — $0 3 2016-10-24
Acer Therapeutics Inc. (OPXAW) Delisted Director 25,884 — — $0 17 2016-10-04
Cougar Biotechnology, Inc. (CGRB) Delisted Director 0 — — $0 2 2009-07-07
Acer Therapeutics Inc. (OPXA) Delisted Director — — — $0 1 2007-06-19

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-03 NXTC Grant (A) — $0 EDGAR
2025-02-03 NXTC Grant (A) — $0 EDGAR
2024-04-02 NXTC Grant (A) — $0 EDGAR
2024-02-01 NXTC Grant (A) — $0 EDGAR
2023-06-23 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2023-03-01 NXTC Grant (A) — $0 EDGAR
2022-06-24 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2022-02-02 NXTC Grant (A) — $0 EDGAR
2021-06-29 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2021-03-16 NXTC Grant (A) — $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.